Traditional life science R&D is fundamentally inefficient, with less than 5% of spending on value-additive reagents and the vast majority wasted on overhead like personnel and lab space.
AI combined with lab automation represents a true platform shift that will revolutionize scientific discovery and disrupt industries like biopharma, which were untouched by previous tech revolutions.
The primary bottleneck in biotech is not biological design but the slow and expensive physical testing of those designs, a problem Ginkgo has pivoted to solve.
The United States is facing intense competition from China in biotechnology, evidenced by China's higher scientific publication volume, dramatically faster clinical trials, and a growing share of biotech innovation.
The cost of R&D can be dramatically improved by using automation to shift spending from overhead to reagents, thereby increasing data output per dollar by up to 10x.
2008
Ginkgo Bioworks is founded and begins operating without venture capital.
2008-2014
The company operates for six years without raising any venture capital, bootstrapping its early development.
2014
Ginkgo Bioworks joins the Y Combinator accelerator program, marking its entry into the venture capital ecosystem.
c. 2021-2023
Kelly states Ginkgo strategically shifted its focus from AI-driven biological design to optimizing the physical lab testing process to be cheaper and faster.
Current
Ginkgo is expanding its Boston lab from 50 to 100 robots and has sold 97 robotic units to the U.S. Department of Energy for Project Genesis.
▶The Inefficiency of Traditional Scientific R&DMay 2026
Kelly argues that the current model for scientific research, particularly in biopharma, is fundamentally broken. He points to massive overhead costs for personnel and lab space, underutilization of expensive equipment, and a focus on incremental improvements rather than disruptive platform changes.
This framing positions Ginkgo's automation-heavy model not just as an improvement, but as a necessary solution to a systemic cost and productivity crisis in a multi-billion dollar industry.
▶AI-Powered Automation as a Paradigm ShiftMay 2026
Kelly views the integration of AI with robotic labs as the next major technological revolution for the life sciences, one that previous tech waves like the internet failed to deliver for the sector. He highlights how AI can translate natural language protocols into robotic actions and optimize experiments, fundamentally changing how science is conducted.
Kelly's focus is less on AI for pure discovery and more on AI as the 'brain' for physical lab infrastructure, suggesting the primary value capture is in owning the automated execution layer of R&D.
▶Ginkgo's Strategic Pivot to Lab InfrastructureMay 2026
Over the last two years, Kelly has shifted Ginkgo's focus from primarily designing biology with AI to making the physical testing of biological designs cheaper and faster. This is manifested in their expansion of robotic labs, their cloud lab service, and selling lab units to government initiatives like Project Genesis.
This strategic shift indicates a move from a pure-play biotech company to a 'biotech-as-a-service' or platform infrastructure provider, potentially creating a more scalable and defensible business model.
▶The Geopolitical Race in Biotechnology
Kelly frequently references the rising scientific and commercial prowess of China, noting its lead in scientific publications, dramatically faster clinical trial timelines, and the increasing proportion of its biotech innovations being acquired by global pharma. He frames US government initiatives like Project Genesis as a direct response to this competitive pressure.
This geopolitical framing suggests that Ginkgo's technology is not just a commercial tool but a strategic asset for national competitiveness, which could unlock significant government contracts and support.